BMRN BioMarin Pharmaceutical Inc. - Common Stock
$68,46
Preço · Ago 19, 2026
Fundamentais a partir de Ago 6, 2026
Intervalo 52 Semanas
$49–$71
88% of range
Classificação do Analista
BUY
33 analysts
Preço-Alvo
$90
+32% upside
P/E (TTM)
38.2
ROE
5.8%
Margem de Lucro Líquido
10.8%
Sobre BioMarin Pharmaceutical Inc. - Common Stock Visão geral da empresa da Wikipedia
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Ler mais
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
History
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
Business development
In 2002, BioMarin acquired Glyko Biomedical.
In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.
In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.
In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
In 2014, BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the intention of advancing work toward therapies for Friedreich's ataxia and other neurological disorders.
In November 2014, the company agreed to the acquisition of Prosensa for up to $840 million; however, the range of treatments for Duchenne muscular dystrophy failed to attain FDA approval, and development ceased in May 2016.
In October 2019 it was revealed that the group will open an office in Dublin to support further growth through Europe, the Middle East and Asia.
In December 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion.
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Products
As of 2022, BioMarin has six products on the market, each of which is an orphan drug.
Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria
Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI)
Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I
Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only)
Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism.
Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017.
Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022.
Biomarin is working to develop several new drugs.
Controversies
In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process.
In 2013, BioMarin Pharmaceuticals was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company.
In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial.
In April 2019, the BBC reported that patients who took part in a trial treatment for the drug Kuvan (sapropterin hydrochloride) were later denied access to it. The company was criticised by the NHS and Stephen Hammond MP for patient profiteering. The company commented the following in response: "BioMarin is disappointed that the NHS England has not recognised the value of treating PKU patients with Kuvan, despite more than a decade of positive patient outcomes across 26 countries in Europe, Russia and Turkey"
In June 2019, a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge. BioMarin stopped providing free Vimizim at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed. This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge. BioMarin was ordered in a preliminary injunction to keep doing so until a definitive judgment would be rendered, or until the medicine would be available on the Belgian market at a reasonable price.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
BMRN Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$68.45
Capitalização de Mercado
$13.23B
P/E (TTM)
38.2
EPS (TTM)
$1.80
Receita (TTM)
$3.22B
Rendimento div.
—
ROE
5.8%
Dívida/Capital
—
Intervalo 52 Semanas
$49 – $71
BMRN Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$3.22B
2016-12-31
→
2025-12-31
EPS
$1.80
2016-12-31
→
2025-12-31
Fluxo de caixa livre
$725M
2016-12-31
→
2025-12-31
Margens
10.8%
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
BMRN
Mediana de Pares
P/E (TTM)
38.2
28.5
P/S (TTM)
4.1
20.1
P/B
2.2
12.9
Price / FCF (Preço / FCF)
18.2
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
BMRN
Mediana de Pares
Operating Margin (Margem Operacional)
12.7%
—
Net Profit Margin (Margem de Lucro Líquido)
10.8%
-48.4%
ROA
4.8%
-28.4%
ROE
5.8%
-49.2%
ROIC
4.9%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
BMRN
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
5.2
5.0
Quick Ratio (Índice de Liquidez Seca)
2.9
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
BMRN
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
12.9%
—
Revenue CAGR 3Y (CAGR Receita 3A)
15.4%
—
Revenue CAGR 5Y (CAGR Receita 5A)
11.6%
—
EPS YoY
-18.6%
—
Net Income YoY (Lucro Líquido Ano a Ano)
-18.3%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
BMRN
Mediana de Pares
BMRN Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
33 analistas
- Compra forte 10 30,3%
- Compra 16 48,5%
- Manter 7 21,2%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
25 analistas · 2026-08-14
Mediana
$86.00
Agora
$68.45
Mín
$60.00
Máx
$124.00
Alvo mediano
$86.00
+25,6%
Alvo médio
$90.32
+31,9%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
-0.17%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $0.73 | $0.70 | 0.03% |
| 31 de Março de 2026 | $0.54 | $0.77 | -0.23% |
| 31 de Dezembro de 2025 | $-0.24 | $0.64 | -0.88% |
| 30 de Setembro de 2025 | $-0.16 | $0.38 | -0.54% |
| 30 de Junho de 2025 | $1.23 | $0.85 | 0.38% |
| 31 de Março de 2025 | $0.95 | $0.72 | 0.23% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Cost of Revenue | $717M | $580M | $532M | $503M | $471M | $524M | $359M | $315M | $242M | $210M | $152M | $122M | |
| R&D Expense | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M | $635M | $462M | |
| SG&A Expense | $1.15B | $1.01B | $892M | $823M | $759M | $738M | $681M | $604M | $554M | $477M | $402M | $302M | |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842M | |
| Operating Income | $409M | $484M | $186M | $161M | $-82M | $-43M | $-100M | $-124M | $-15M | $-803M | $-111M | $-93M | |
| Interest Expense | · | · | $17M | $16M | $15M | $29M | $23M | $44M | $43M | $39M | $38M | $37M | |
| Interest Income | $75M | $75M | $58M | $18M | $10M | $17M | $23M | $23M | $15M | $7M | $5M | $6M | |
| Pretax Income | $482M | $542M | $189M | $150M | $-75M | $-49M | $-95M | $-143M | $-36M | $-831M | $-155M | $-125M | |
| Income Tax | $134M | $115M | $21M | $8M | $-11M | $-903M | $-71M | $-65M | $81M | $-201M | $17M | $9M | |
| Net Income | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 | |
| Shares (Basic) | 191,787,000 | 190,027,000 | 187,834,000 | 185,266,000 | 182,852,000 | 180,804,000 | 179,039,000 | 177,061,000 | 174,427,000 | 165,985,000 | 160,025,000 | 146,349,000 | |
| Shares (Diluted) | 197,394,000 | 196,708,000 | 191,595,000 | 188,963,000 | 182,852,000 | 191,678,000 | 179,039,000 | 177,268,000 | 174,427,000 | 166,219,000 | 160,025,000 | 146,349,000 | |
| EBITDA | $489M | $581M | $262M | $252M | $26M | $68M | $5M | $-28M | $73M | $-707M | $-64M | $-93M |
Balanço Patrimonial 28
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $943M | $755M | $725M | $587M | $649M | $437M | $494M | $598M | $408M | $397M | $875M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $798M | $381M | $196M | $70M | |
| Receivables | $908M | $661M | $634M | $461M | $373M | $448M | $377M | $343M | $261M | $215M | $165M | $144M | |
| Inventory | $1.30B | $1.23B | $1.11B | $894M | $777M | $699M | $680M | $531M | $476M | $355M | $272M | $199M | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | · | $28M | $35M | |
| Other Current Assets | $186M | $202M | $141M | $105M | $110M | $130M | $131M | $98M | $74M | $62M | $60M | $109M | |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B | $1.09B | $1.40B | |
| PP&E (Net) | $953M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $949M | $897M | $799M | $704M | $524M | |
| PP&E (Gross) | $2.03B | $1.93B | $1.93B | $1.88B | $1.76B | $1.67B | $1.56B | $1.42B | $1.30B | $1.14B | $983M | $752M | |
| Accum. Depreciation | $1.07B | $892M | $867M | $802M | $721M | $636M | $549M | $473M | $407M | $343M | $279M | $229M | |
| Goodwill | $196M | $196M | $196M | $196M | $196M | $196M | $197M | $197M | $197M | $197M | $197M | $54M | |
| Intangibles | $214M | $255M | $295M | $339M | $389M | $417M | $457M | $492M | $518M | $554M | $684M | $157M | |
| Other Non-current Assets | $277M | $251M | $172M | $176M | $152M | $142M | $122M | $37M | $30M | $33M | $409M | $55M | |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Accounts Payable | $759M | $607M | $683M | $573M | $498M | $493M | $571M | $437M | $402M | $371M | $393M | $232M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $98M | |
| Current Liabilities | $759M | $607M | $1.18B | $589M | $546M | $493M | $933M | $523M | $817M | $439M | $445M | $236M | |
| Capital Leases | $37M | $31M | $38M | $26M | $32M | $40M | $44M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $144M | · | |
| Other Non-current Liabilities | $151M | $129M | $120M | $100M | $98M | $114M | $98M | $59M | $59M | $42M | $45M | $30M | |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B | $1.33B | $947M | |
| Long-term Debt | $597M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $192.0K | $191.0K | $189.0K | $186.0K | $184.0K | $182.0K | $180.0K | $178.0K | $176.0K | $173.0K | $162.0K | $149.0K | |
| Retained Earnings | $154M | $-195M | $-622M | $-789M | $-931M | $-862M | $-1.72B | $-1.69B | $-1.64B | $-1.52B | $-1.02B | $-850M | |
| AOCI | $-13M | $62M | $-29M | $-4M | $14M | $-16M | $20M | $5M | $-23M | $13M | $21M | $27M | |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B | $2.40B | $1.53B | |
| Liabilities + Equity | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Shares Outstanding | 192,300,101 | 190,761,000 | 188,598,000 | 186,251,000 | 183,913,000 | 181,741,000 | 179,838,000 | 178,252,954 | 175,843,749 | 172,647,588 | 161,526,044 | 149,093,647 |
Fluxo de Caixa 16
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $80M | $96M | $104M | $102M | $108M | $105M | $105M | $96M | $88M | $97M | $47M | $46M | |
| Stock-based Comp | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M | $112M | $86M | |
| Deferred Tax | $49M | $56M | $-45M | $-52M | $-16M | $-890M | $-83M | $-68M | $44M | $-228M | $-77M | $-26M | |
| Amort. of Intangibles | $19M | $43M | $62M | $67M | · | · | · | · | · | · | · | $10M | |
| Other Non-cash | $169M | $-208M | $-275M | $-212M | $79M | $-180M | $-110M | $-79M | $-164M | $399M | $-132M | · | |
| Operating Cash Flow | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | $-9M | $-228M | $-219M | $-70M | |
| CapEx | $103M | $85M | $97M | $121M | $96M | $114M | $145M | $145M | $199M | $148M | $228M | $117M | |
| Investing Cash Flow | $-414M | $136M | $-111M | $-20M | $-366M | $-54M | $-31M | $264M | $-305M | $-484M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $713M | $888M | $117M | |
| Stock Repurchased | · | · | · | $0 | $0 | $50M | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | · | · | $0 | $0 | $-50M | · | $0 | $0 | $713M | $888M | $117M | |
| Financing Cash Flow | $-42M | $-526M | $-19M | $-19M | $-48.0K | $181M | $-75M | $-388M | $507M | $727M | · | · | |
| Net Change in Cash | $369M | $188M | $31M | $137M | $-62M | $212M | $-57M | $-104M | $190M | $11M | $-478M | $307M | |
| Taxes Paid | $96M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M | $-29M | $-97M | $-124M | $-208M | $-376M | $-449M | $-192M | |
| Levered FCF | · | · | $47M | $40M | $196M | $566M | $-103M | $-148M | $-347M | $-406M | $-492M | $-232M |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.8% | |
| Pretax Margin | 15.0% | 19.0% | 7.8% | 7.1% | -4.1% | -2.3% | -5.6% | -9.6% | -2.7% | -74.4% | -17.4% | -16.6% | |
| EBITDA Margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% | 0.28% | -1.9% | 5.6% | -63.3% | -7.1% | -12.4% | |
| ROA | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.3% | -0.52% | -1.7% | -2.7% | -16.3% | -5.5% | -5.7% | |
| ROE | 5.8% | 7.7% | 3.4% | 3.1% | -1.5% | 21.1% | -0.77% | -2.6% | -4.2% | -24.4% | -8.8% | -9.3% | |
| ROIC | 4.9% | 6.7% | 2.8% | 3.1% | -1.6% | 18.2% | -0.81% | -2.2% | -1.7% | -22.0% | -5.1% | -6.5% |
Liquidez e Solvência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 | 4.8 | 2.1 | 3.9 | 2.7 | 3.2 | 2.4 | 6.0 | |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 | 2.2 | 0.9 | 1.6 | 2.0 | 2.3 | 1.7 | 4.6 | |
| Interest Coverage | · | · | 9.1 | 9.4 | -5.4 | -1.3 | -4.3 | -2.8 | -0.3 | -20.3 | -2.9 | -2.5 |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.5 | 4.5 | 4.7 | 4.9 | 5.5 | 5.9 | 5.8 | 5.7 |
Taxas de Crescimento 9
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 12.9% | 18.0% | 15.4% | 13.5% | -0.76% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 15.4% | 15.6% | 9.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -18.6% | 154.0% | 16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 33.9% | · | -42.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -18.3% | 154.6% | 18.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | -41.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Net Income TTM | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| Market Cap | $11.43B | $12.54B | $18.18B | $19.28B | $16.25B | $15.94B | $15.21B | $15.18B | $15.68B | $14.30B | $16.92B | $13.48B | |
| P/E | 33.0 | 29.7 | 110.8 | 138.0 | -252.4 | 19.5 | -650.4 | -193.5 | -133.1 | -21.7 | -97.9 | -98.3 | |
| P/S | 3.5 | 4.4 | 7.5 | 9.2 | 8.8 | 8.6 | 8.9 | 10.2 | 11.9 | 12.8 | 19.0 | 18.0 | |
| P/B | 1.9 | 2.2 | 3.7 | 4.2 | 3.8 | 3.9 | 4.9 | 5.1 | 5.6 | 5.2 | 7.0 | 8.8 | |
| P / Tangible Book | 2.0 | 2.4 | 4.1 | 4.7 | 4.4 | 4.6 | · | · | · | · | · | · | |
| P / Cash Flow | 13.8 | 21.9 | 114.2 | 109.6 | 53.4 | 186.7 | 315.1 | 751.1 | -1790.6 | -62.8 | -76.3 | -183.3 | |
| P / FCF | 15.8 | 25.7 | 290.6 | 350.8 | 77.8 | -550.6 | -157.1 | -122.0 | -75.4 | -38.0 | -37.7 | -70.1 | |
| Earnings Yield | 3.0% | 3.4% | 0.90% | 0.72% | -0.40% | 5.1% | -0.15% | -0.52% | -0.75% | -4.6% | -1.0% | -1.0% |
Demonstração de Resultados 16
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M | $649M | $646M | $581M | $595M | $596M | $538M | $505M | |
| Cost of Revenue | $203M | $195M | $276M | $140M | $150M | $152M | $136M | $188M | $130M | $125M | $138M | $128M | $131M | $135M | $147M | $116M | |
| R&D Expense | $207M | $179M | $192M | $409M | $161M | $159M | $174M | $185M | $184M | $205M | $206M | $191M | $177M | $172M | $173M | $158M | |
| SG&A Expense | $396M | $258M | $446M | $268M | $232M | $206M | $267M | $253M | $263M | $226M | $260M | $216M | $206M | $211M | $215M | $217M | |
| Operating Expenses | $879M | $637M | $919M | $823M | $549M | $521M | $586M | $632M | $592M | $560M | $619M | $551M | $530M | $534M | $551M | $508M | |
| Operating Income | $111M | $130M | $-45M | $-47M | $277M | $224M | $161M | $114M | $120M | $88M | $27M | $31M | $66M | $62M | $-13M | $-2M | |
| Interest Expense | $61M | $10M | · | · | $2M | $2M | · | · | · | $4M | · | $4M | $4M | $4M | · | $5M | |
| Interest Income | $10M | $23M | $19M | $18M | $19M | $19M | $18M | $18M | $20M | $19M | $18M | $16M | $13M | $12M | $9M | $5M | |
| Pretax Income | $61M | $141M | $-27M | $-26M | $298M | $238M | $170M | $134M | $132M | $106M | $19M | $42M | $71M | $57M | $-18M | $-2M | |
| Income Tax | $17M | $36M | $19M | $4M | $57M | $52M | $45M | $28M | $25M | $17M | $-1M | $1M | $15M | $6M | $-17M | $5M | |
| Net Income | $45M | $106M | $-47M | $-31M | $241M | $186M | $125M | $106M | $107M | $89M | $20M | $40M | $56M | $51M | $-249.0K | $-7M | |
| EPS (Basic) | $0.23 | $0.55 | $-0.24 | $-0.16 | $1.25 | $0.97 | $0.66 | $0.56 | $0.56 | $0.47 | $0.11 | $0.21 | $0.30 | $0.27 | $-0.01 | $-0.04 | |
| EPS (Diluted) | $0.23 | $0.54 | $-0.22 | $-0.16 | $1.23 | $0.95 | $0.65 | $0.55 | $0.55 | $0.46 | $0.10 | $0.21 | $0.29 | $0.27 | $0.01 | $-0.04 | |
| Shares (Basic) | 193,423,000 | 192,497,000 | -383,119,000 | 192,032,000 | 191,907,000 | 190,967,000 | -379,382,000 | 190,429,000 | 190,114,000 | 188,866,000 | -375,000,000 | 188,219,000 | 187,948,000 | 186,667,000 | -369,575,000 | 185,597,000 | |
| Shares (Diluted) | 194,467,000 | 197,671,000 | -388,203,000 | 192,032,000 | 197,091,000 | 196,474,000 | -400,206,000 | 197,147,000 | 200,505,000 | 199,262,000 | -388,939,000 | 191,173,000 | 194,998,000 | 194,363,000 | -378,968,000 | 185,597,000 | |
| EBITDA | $111M | $146M | · | $-47M | $277M | $246M | · | $114M | $120M | $116M | · | $26M | $59M | $86M | · | $-2M |
Balanço Patrimonial 25
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $943M | $675M | $972M | $747M | · | $785M | $694M | $580M | · | $762M | |
| Receivables | $1.06B | $904M | $908M | $790M | $856M | $739M | $661M | $778M | $691M | $637M | · | $572M | $610M | $598M | · | $420M | |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | · | $1.03B | $976M | $919M | · | $839M | |
| Other Current Assets | $254M | $206M | $186M | $204M | $177M | $182M | $202M | $169M | $160M | $163M | · | $225M | $193M | $173M | · | $150M | |
| Current Assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | · | $2.96B | $2.95B | $2.84B | · | $2.68B | |
| PP&E (Net) | $990M | $958M | $953M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | · | $1.07B | $1.07B | $1.07B | · | $1.05B | |
| PP&E (Gross) | $2.10B | $2.05B | $2.03B | $1.99B | $1.96B | $1.94B | $1.93B | $1.91B | $1.96B | $1.95B | · | $1.92B | $1.90B | $1.88B | · | $1.83B | |
| Accum. Depreciation | $1.11B | $1.09B | $1.07B | $950M | $931M | $908M | $892M | $869M | $910M | $888M | · | $851M | $829M | $807M | · | $782M | |
| Goodwill | $656M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | · | $196M | $196M | $196M | · | $196M | |
| Intangibles | $4.88B | $205M | $214M | $233M | $240M | $247M | $255M | $261M | $266M | $280M | · | $302M | $310M | $326M | · | $354M | |
| Other Non-current Assets | $338M | $276M | $277M | $271M | $249M | $236M | $251M | $199M | $191M | $185M | · | $165M | $144M | $150M | · | $152M | |
| Total Assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Accounts Payable | $1.01B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $572M | $594M | · | $670M | $597M | $598M | · | $493M | |
| Current Liabilities | $1.66B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $1.07B | $1.09B | · | $1.16B | $597M | $598M | · | $521M | |
| Capital Leases | · | · | $37M | · | · | · | $31M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $210M | $155M | $151M | $163M | $149M | $130M | $129M | $128M | $119M | $117M | · | $105M | $98M | $92M | · | $92M | |
| Total Liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | · | $1.86B | $1.78B | $1.77B | · | $1.70B | |
| Long-term Debt | $4.19B | $1.43B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $4.19B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $194.0K | $193.0K | $192.0K | $192.0K | $192.0K | $192.0K | $191.0K | $191.0K | $190.0K | $190.0K | · | $188.0K | $188.0K | $188.0K | · | $186.0K | |
| Retained Earnings | $304M | $260M | $154M | $201M | $232M | $-9M | $-195M | $-320M | $-426M | $-533M | · | $-642M | $-682M | $-738M | · | $-789M | |
| AOCI | $-9M | $-4M | $-13M | $-34M | $-45M | $19M | $62M | $5M | $27M | $-1M | · | $6M | $-19M | $-11M | · | $31M | |
| Stockholders' Equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B | $4.78B | $4.66B | $4.60B | $4.57B | |
| Liabilities + Equity | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Shares Outstanding | 193,535,556 | 193,268,870 | 192,300,101 | 192,098,751 | 192,001,650 | 191,755,802 | 190,761,349 | 190,553,918 | 190,355,517 | 189,776,577 | 188,598,000 | 188,339,482 | 188,151,695 | 187,601,106 | 186,251,000 | 185,824,253 |
Fluxo de Caixa 13
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $98M | $16M | $20M | $18M | $19M | $22M | $24M | $19M | $26M | $27M | $27M | $26M | $25M | $26M | $25M | $25M | |
| Stock-based Comp | $76M | $43M | $47M | $49M | $48M | $38M | $52M | $43M | $48M | $58M | $55M | $48M | $50M | $54M | $47M | $55M | |
| Deferred Tax | $-7M | $9M | $613.0K | $-14M | $33M | $28M | $42M | $12M | $1M | $285.0K | $-25M | $-15M | $1M | $-6M | $-51M | $-4M | |
| Amort. of Intangibles | $73M | $4M | $5M | $5M | $5M | $5M | $10M | $5M | $14M | $14M | $15M | $16M | $16M | $16M | · | · | |
| Restructuring | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $46M | · | · | · | $-99M | · | · | · | $-128M | · | · | · | $-199M | · | · | |
| Operating Cash Flow | $168M | $221M | $100M | $369M | $185M | $174M | $186M | $221M | $119M | $47M | $27M | $136M | $70M | $-74M | $7M | $158M | |
| CapEx | $29M | $21M | $41M | $28M | $17M | $17M | $20M | $18M | $21M | $26M | $29M | $22M | $22M | $24M | $36M | $29M | |
| Investing Cash Flow | $-5.10B | $726M | $-42M | $-331M | $-13M | $-28M | $76M | $-16M | $90M | $-14M | $-65M | $-46M | $30M | $-30M | $-55M | $-23M | |
| Financing Cash Flow | $2.74B | $813M | $3M | $-2M | $-5M | $-39M | $3M | $-499M | $13M | $-43M | $11M | $-788.0K | $12M | $-41M | $11M | $8M | |
| Net Change in Cash | $-2.20B | $1.76B | $62M | $36M | $165M | $106M | $267M | $-297M | $225M | $-8M | $-30M | $91M | $114M | $-144M | $-37M | $142M | |
| Free Cash Flow | · | $200M | · | · | · | $158M | · | · | · | $21M | · | · | · | $-98M | · | · | |
| Levered FCF | · | $193M | · | · | · | · | · | · | · | $18M | · | · | · | $-102M | · | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.2% | 16.9% | · | -6.0% | 33.6% | 30.0% | · | 15.3% | 16.9% | 13.6% | · | 4.4% | 9.9% | 10.0% | · | -0.48% | |
| Net Margin | 4.5% | 13.8% | · | -4.0% | 29.1% | 24.9% | · | 14.2% | 15.0% | 13.7% | · | 7.0% | 9.4% | 8.5% | · | -1.3% | |
| Pretax Margin | 6.2% | 18.4% | · | -3.4% | 36.1% | 31.9% | · | 18.0% | 18.6% | 16.3% | · | 7.2% | 11.9% | 9.5% | · | -0.38% | |
| EBITDA Margin | 11.2% | 19.1% | · | -6.0% | 33.6% | 33.0% | · | 15.3% | 16.9% | 17.8% | · | 4.4% | 9.9% | 14.4% | · | -0.48% | |
| ROA | 0.47% | 1.3% | · | -0.43% | 3.3% | 2.6% | · | 1.6% | 1.6% | 1.3% | · | 0.62% | 0.88% | 0.81% | · | -0.11% | |
| ROE | 0.72% | 1.8% | · | -0.54% | 4.2% | 3.4% | · | 2.1% | 2.1% | 1.8% | · | 0.85% | 1.2% | 1.1% | · | -0.15% | |
| ROIC | 0.77% | 1.6% | · | -0.90% | 3.7% | 3.0% | · | 1.7% | 1.8% | 1.5% | · | 0.51% | 0.97% | 1.1% | · | -0.18% |
Liquidez e Solvência 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 5.8 | · | 4.8 | 5.6 | 5.5 | · | 4.3 | 3.1 | 2.7 | · | 2.5 | 4.9 | 4.8 | · | 5.1 | |
| Quick Ratio | 1.2 | 3.9 | · | 2.6 | 3.0 | 2.8 | · | 2.0 | 1.6 | 1.3 | · | 1.2 | 2.2 | 2.0 | · | 2.3 | |
| Debt / Equity | 0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | 1.8 | 13.5 | · | · | · | · | · | · | · | 24.9 | · | 6.8 | 15.7 | 16.0 | · | -0.5 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.1 | 1.2 | · | 1.3 |
Avaliação (TTM) 13
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.36B | $3.11B | · | $3.09B | $3.03B | $2.85B | · | $2.69B | $2.54B | $2.42B | · | $2.28B | $2.23B | $2.15B | · | $1.97B | |
| Net Income TTM | $360M | $501M | · | $502M | $639M | $488M | · | $342M | $292M | $236M | · | $141M | $128M | $193M | · | $105M | |
| Market Cap | $11.07B | $10.92B | · | $10.40B | $10.55B | $13.56B | · | $13.39B | $15.67B | $16.58B | · | $16.66B | $16.31B | $18.24B | · | $15.75B | |
| Enterprise Value | $14.39B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 31.1 | 22.1 | · | 21.1 | 16.8 | 28.2 | · | 39.7 | 54.5 | 71.0 | · | 121.2 | 129.4 | 96.3 | · | 157.0 | |
| P/S | 3.3 | 3.5 | · | 3.4 | 3.5 | 4.8 | · | 5.0 | 6.2 | 6.8 | · | 7.3 | 7.3 | 8.5 | · | 8.0 | |
| P/B | 1.8 | 1.8 | · | 1.7 | 1.8 | 2.3 | · | 2.5 | 3.0 | 3.3 | · | 3.4 | 3.4 | 3.9 | · | 3.4 | |
| P / Tangible Book | 14.1 | 1.9 | · | 1.8 | 1.9 | 2.5 | · | 2.7 | 3.2 | 3.6 | · | 3.8 | 3.8 | 4.4 | · | 3.9 | |
| P / Cash Flow | · | 49.5 | · | · | · | 77.7 | · | · | · | 352.9 | · | · | · | -246.7 | · | · | |
| P / FCF | · | 54.7 | · | · | · | 86.0 | · | · | · | 794.3 | · | · | · | -185.4 | · | · | |
| EV / EBITDA | 129.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 4.3 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 3.2% | 4.5% | · | 4.8% | 6.0% | 3.5% | · | 2.5% | 1.8% | 1.4% | · | 0.83% | 0.77% | 1.0% | · | 0.64% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Margem Operacional % | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% |
| Lucro líquido | $349M | $427M | $168M | $142M | $-64M |
| EPS Diluído | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 |
| Índice de Liquidez Seca | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $725M | $487M | $63M | $55M | $209M |
Últimas notícias Notícias recentes mencionando esta empresa
- Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
- A BioMarin Pharmaceutical Inc. (BMRN) é uma das principais ações baratas para comprar com o maior potencial de alta?
- BioMarin nomeia Ian Clark como presidente do conselho
- BioMarin Pharmaceutical (BMRN) Reporta Resultados Positivos dos Ensaios Clínicos em Andamento do VOXZOGO
Sinais de trading Sinais recentes de compra/venda com preço de entrada e relação risco/recompensa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 616 declarantes · $8.6B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 96 (+2 vs trimestre anterior) | 74 (+9 vs trimestre anterior) | 191 (-17 vs trimestre anterior) | 204 (+39 vs trimestre anterior) | +28.9M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| Dodge & Cox | $849.426.895 | 14.844.930 | 9,87% | Ações |
| PRIMECAP MANAGEMENT CO/CA/ | $811.962.329 | 14.190.183 | 9,44% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $500.310.680 | 8.743.633 | 5,82% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $494.877.355 | 8.648.678 | 5,75% | Ações |
| NORGES BANK | $469.659.128 | 8.207.954 | 5,46% | Ações |
| STATE STREET CORP | $446.370.874 | 7.800.959 | 5,19% | Ações |
| VIKING GLOBAL INVESTORS LP | $435.819.735 | 7.616.563 | 5,07% | Ações |
| Vestal Point Capital, LP | $344.750.500 | 6.025.000 | 4,01% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $216.743.752 | 3.787.902 | 2,52% | Ações |
| Capital Research Global Investors | $200.521.024 | 3.504.387 | 2,33% | Ações |
| FMR LLC | $196.878.227 | 3.440.724 | 2,29% | Ações |
| Deep Track Capital, LP | $189.254.063 | 3.307.481 | 2,20% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $180.073.856 | 3.146.120 | 2,09% | Ações |
| MILLENNIUM MANAGEMENT LLC | $118.549.312 | 2.071.816 | 1,38% | Ações |
| Assenagon Asset Management S.A. | $100.826.561 | 1.762.086 | 1,17% | Ações |
| FIRST TRUST ADVISORS LP | $91.910.897 | 1.606.273 | 1,07% | Ações |
| Jones Hill Capital LP | $81.915.580 | 1.431.590 | 0,95% | Ações |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $76.264.876 | 1.332.836 | 0,89% | Ações |
| Swedbank AB | $75.232.112 | 1.314.787 | 0,87% | Ações |
| DNB Asset Management AS | $72.566.061 | 1.268.194 | 0,84% | Ações |
| Caisse de depot et placement du Quebec | $70.749.440 | 1.236.446 | 0,82% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $70.030.356 | 1.223.879 | 0,81% | Ações |
| AMERIPRISE FINANCIAL INC | $65.664.916 | 1.147.544 | 0,76% | Ações |
| CITADEL ADVISORS LLC | $64.224.186 | 1.122.408 | 0,75% | Ações |
| Balyasny Asset Management L.P. | $60.344.956 | 1.054.613 | 0,70% | Ações |
| ARGA Investment Management, LP | $59.474.983 | 1.039.409 | 0,69% | Ações |
| GOLDMAN SACHS GROUP INC | $56.321.074 | 984.290 | 0,65% | Ações |
| Brandywine Global Investment Management, LLC | $56.211.687 | 945.847 | 0,65% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $54.484.884 | 952.200 | 0,63% | Opção de compra |
| MACKENZIE FINANCIAL CORP | $53.321.258 | 931.864 | 0,62% | Ações |
| FRANKLIN RESOURCES INC | $47.889.936 | 836.944 | 0,56% | Ações |
| Hudson Bay Capital Management LP | $47.206.500 | 825.000 | 0,55% | Ações |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $40.949.264 | 715.646 | 0,48% | Ações |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $39.869.980 | 696.784 | 0,46% | Ações |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $39.311.857 | 687.030 | 0,46% | Ações |
| Palo Alto Investors LP | $39.068.500 | 682.777 | 0,45% | Ações |
| Defilade Capital Management, L.P. | $39.024.326 | 682.005 | 0,45% | Ações |
| Qube Research & Technologies Ltd | $38.270.739 | 668.835 | 0,44% | Ações |
| Eagle Health Investments LP | $35.743.961 | 624.676 | 0,42% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $34.419.661 | 601.532 | 0,40% | Ações |
| BOONE CAPITAL MANAGEMENT LLC | $33.371.791 | 583.219 | 0,39% | Ações |
| Camber Capital Management LP | $32.982.000 | 600.000 | 0,38% | Ações |
| River Road Asset Management, LLC | $31.069.888 | 542.990 | 0,36% | Ações |
| RHUMBLINE ADVISERS | $29.570.438 | 516.786 | 0,34% | Ações |
| Trails Edge Capital Partners, LP | $29.296.640 | 512.000 | 0,34% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $28.048.615 | 490.189 | 0,33% | Ações |
| Jefferies Financial Group Inc. | $26.679.283 | 466.258 | 0,31% | Ações |
| LOOMIS SAYLES & CO L P | $25.986.177 | 454.145 | 0,30% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $25.856.059 | 451.871 | 0,30% | Ações |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $25.588.784 | 447.200 | 0,30% | Ações |
| California Public Employees Retirement System | $25.124.959 | 439.094 | 0,29% | Ações |
| Rockefeller Capital Management L.P. | $24.797.775 | 433.376 | 0,29% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24.038.122 | 420.100 | 0,28% | Opção de venda |
| SEB Asset Management AB | $23.583.178 | 412.150 | 0,27% | Ações |
| Robeco Institutional Asset Management B.V. | $23.358.064 | 408.215 | 0,27% | Ações |
| Pictet Asset Management Holding SA | $22.789.414 | 395.382 | 0,26% | Ações |
| BlackRock, Inc. | $22.697.229 | 396.666 | 0,26% | Ações |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $22.513.495 | 393.455 | 0,26% | Ações |
| PRUDENTIAL FINANCIAL INC | $22.325.585 | 390.171 | 0,26% | Ações |
| Soleus Capital Management, L.P. | $21.490.230 | 375.572 | 0,25% | Ações |
| Freestone Grove Partners LP | $20.839.181 | 364.194 | 0,24% | Ações |
| Sofinnova Investments, Inc. | $20.517.261 | 358.568 | 0,24% | Ações |
| Swiss National Bank | $20.427.540 | 357.000 | 0,24% | Ações |
| LAZARD ASSET MANAGEMENT LLC | $20.049.716 | 350.397 | 0,23% | Ações |
| BANK OF AMERICA CORP /DE/ | $19.371.831 | 338.550 | 0,23% | Ações |
| EASTERLY INVESTMENT PARTNERS LLC | $18.847.524 | 329.387 | 0,22% | Ações |
| SPHERA FUNDS MANAGEMENT LTD. | $18.799.631 | 328.550 | 0,22% | Ações |
| DIADEMA PARTNERS LP | $17.901.048 | 312.846 | 0,21% | Ações |
| SECTOR GAMMA AS | $16.875.208 | 294.918 | 0,20% | Ações |
| Rhenman & Partners Asset Management AB | $16.622.410 | 290.500 | 0,19% | Ações |
| Walleye Capital LLC | $16.492.692 | 288.233 | 0,19% | Ações |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $16.114.296 | 281.620 | 0,19% | Ações |
| ALLIANCEBERNSTEIN L.P. | $16.009.266 | 283.400 | 0,19% | Ações |
| Bridgewater Associates, LP | $15.730.407 | 274.911 | 0,18% | Ações |
| Susquehanna Portfolio Strategies, LLC | $15.653.218 | 273.562 | 0,18% | Ações |
| Redmile Group, LLC | $15.172.970 | 265.169 | 0,18% | Ações |
| Amundi | $14.864.727 | 259.782 | 0,17% | Ações |
| Eversept Partners, LP | $14.282.513 | 249.607 | 0,17% | Ações |
| Distillate Capital Partners LLC | $14.242.974 | 248.916 | 0,17% | Ações |
| RICE HALL JAMES & ASSOCIATES, LLC | $14.203.377 | 248.224 | 0,17% | Ações |
| CAPITAL FUND MANAGEMENT S.A. | $13.470.789 | 235.421 | 0,16% | Ações |
| CITADEL ADVISORS LLC | $13.189.210 | 230.500 | 0,15% | Opção de compra |
| CANADA PENSION PLAN INVESTMENT BOARD | $12.868.778 | 224.900 | 0,15% | Ações |
| M&G PLC | $12.317.472 | 216.096 | 0,14% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12.137.385 | 214.859 | 0,14% | Ações |
| GLENMEDE TRUST CO NA | $11.782.055 | 205.908 | 0,14% | Ações |
| Retirement Systems of Alabama | $11.438.907 | 199.911 | 0,13% | Ações |
| IEQ CAPITAL, LLC | $11.328.874 | 197.988 | 0,13% | Ações |
| Mariner, LLC | $11.021.160 | 192.607 | 0,13% | Ações |
| Monaco Asset Management SAM | $10.582.095 | 184.937 | 0,12% | Ações |
| Engineers Gate Manager LP | $10.393.841 | 181.647 | 0,12% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $9.840.867 | 171.983 | 0,11% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $9.713.000 | 169.746 | 0,11% | Ações |
| RAYMOND JAMES FINANCIAL INC | $9.595.050 | 167.687 | 0,11% | Ações |
| VAN ECK ASSOCIATES CORP | $9.444.504 | 165.056 | 0,11% | Ações |
| PEREGRINE CAPITAL MANAGEMENT LLC | $9.310.495 | 162.714 | 0,11% | Ações |
| CWM, LLC | $9.018.745 | 159.652 | 0,10% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9.015.469 | 157.558 | 0,10% | Ações |
| BARCLAYS PLC | $8.865.839 | 154.943 | 0,10% | Ações |
| Legal & General Group Plc | $8.722.675 | 152.441 | 0,10% | Ações |
Executivos da empresa 48 insiders · 19 diretores · 29 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | 17 de Março de 2025 A | 175.583 | 0 | 0 | $0 |
| Louis Drapeau | Chief Executive Officer | 2 de Maio de 2005 A | 14.934 | 0 | 0 | $0 |
| Fredric D Price | Chief Executive Officer | 6 de Maio de 2004 P | 79.285 | 0 | 0 | $0 |
| Brian Mueller | EVP, Chief Financial Officer | 17 de Março de 2025 A | 99.781 | 0 | 0 | $0 |
| Daniel K Spiegelman | EVP, Chief Financial Officer | 22 de Junho de 2018 S | 51.070 | 0 | 0 | $0 |
| Jeffrey H Cooper | SVP, Chief Financial Officer | 14 de Maio de 2012 M | 41.089 | 0 | 0 | $0 |
| Henry J Fuchs | President, Worldwide R&D | 13 de Setembro de 2024 F | 185.074 | 0 | 0 | $0 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 20 de Maio de 2025 F | 30.545 | 0 | 0 | $0 |
| Erin Burkhart | GVP, Chief Accounting Officer | 20 de Maio de 2025 S | 14.173 | 0 | 0 | $0 |
| Gregory R Friberg | EVP, Chief R&D Officer | 17 de Março de 2025 A | 46.810 | 0 | 0 | $0 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 17 de Março de 2025 A | 80.838 | 0 | 0 | $0 |
| George Eric Davis | EVP, Chief Legal Officer | 17 de Março de 2025 A | 82.915 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | 2 de Maio de 2024 S | 66.767 | 0 | 0 | $0 |
| Robert Baffi | EVP, Technical Operations | 22 de Junho de 2018 M | 83.276 | 0 | 0 | $0 |
| Steve Aselage | EVP, Chief Business Officer | 2 de Julho de 2012 M | 59.030 | 0 | 0 | $0 |
| Emil D Kakkis | Chief Medical Officer | 2 de Março de 2009 M | 39.621 | 0 | 0 | $0 |
| Stuart J Swiedler | SVP, Clinical Affairs | 7 de Julho de 2008 A | 12.000 | 0 | 0 | $0 |
| Christopher M Starr | SVP, Chief Scientific Officer | 1 de Dezembro de 2005 M | 295.176 | 0 | 0 | $0 |
| Jeffrey Landau | SVP, Administration | 31 de Outubro de 2004 A | 2.740 | 0 | 0 | $0 |
| Elizabeth M Anderson | Conselheiro | 2 de Junho de 2026 A | 41.940 | 0 | 0 | $0 |
| Barbara W. Bodem | Conselheiro | 2 de Junho de 2026 A | 21.045 | 0 | 0 | $0 |
| Maykin Ho | Conselheiro | 2 de Junho de 2026 A | 35.500 | 0 | 0 | $0 |
| Mark J Enyedy | Conselheiro | 2 de Junho de 2026 A | 21.040 | 0 | 0 | $0 |
| Athena Countouriotis | Conselheiro | 2 de Junho de 2026 A | 21.040 | 0 | 0 | $0 |
| Robert J. Hombach | Conselheiro | 2 de Junho de 2026 A | 49.360 | 0 | 0 | $0 |
| Timothy P Walbert | Conselheiro | 2 de Junho de 2026 A | 17.270 | 0 | 0 | $0 |
| Ian T Clark | Conselheiro | 2 de Junho de 2026 A | 14.490 | 0 | 0 | $0 |
| Willard H Dere | Conselheiro | 2 de Junho de 2026 A | 46.440 | 0 | 0 | $0 |
| Richard A Meier | Conselheiro | 20 de Maio de 2025 A | 127.426 | 0 | 0 | $0 |
| Elaine J Heron | Conselheiro | 3 de Junho de 2024 M | 97.720 | 0 | 0 | $0 |
| David E I Pyott | Conselheiro | 21 de Maio de 2024 A | 49.750 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Conselheiro | 20 de Maio de 2024 F | 473.792 | 0 | 0 | $0 |
| Dennis Slamon | Conselheiro | 18 de Março de 2024 M | 31.299 | 0 | 0 | $0 |
| Mark J Alles | Conselheiro | 23 de Maio de 2023 A | 15.095 | 0 | 0 | $0 |
| Bryan V Lawlis | Conselheiro | 23 de Maio de 2023 A | 33.140 | 0 | 0 | $0 |
| Michael G Grey | Conselheiro | 5 de Junho de 2018 A | 34.110 | 0 | 0 | $0 |
| Alan Lewis | Conselheiro | 5 de Junho de 2018 A | 25.360 | 0 | 0 | $0 |
| Kathryn E Falberg | Conselheiro | 15 de Julho de 2016 A | 2.640 | 0 | 0 | $0 |
| William D Young | Conselheiro | 10 de Junho de 2015 A | 11.875 | 0 | 0 | $0 |
| Kenneth Bate | Conselheiro | 10 de Junho de 2015 A | 11.875 | 0 | 0 | $0 |
| Pierre Lapalme | Conselheiro | 10 de Junho de 2015 A | 31.250 | 0 | 0 | $0 |
| Joseph Klein III | Conselheiro | 8 de Março de 2010 S | 35.000 | 0 | 0 | $0 |
| Franz L Cristiani | Conselheiro | 14 de Junho de 2006 A | — | 0 | 0 | $0 |
| Erich Sager | Conselheiro | 24 de Fevereiro de 2006 M | 3.309 | 0 | 0 | $0 |
| Gwynn Williams | Conselheiro | 30 de Novembro de 2004 A | 812.565 | 0 | 0 | $0 |
| John Urquhart | Conselheiro | 28 de Julho de 2004 A | — | 0 | 0 | $0 |
| BIOMARIN PHARMACEUTICAL INC | Detentor de 10% | 8 de Dezembro de 2012 J | 6.666.667 | 0 | 0 | $0 |
| Mark Wood | — | 22 de Maio de 2013 M | 20.277 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 4 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc., BioMarin Falcons B.V., BioMarin Giants B.V. ×5 declarações | 2 de Fevereiro de 2015 | — | Declaração inicial | — | SEC |
| Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC, Israel A. Englander ×2 declarações | 31 de Julho de 2009 | — | Declaração inicial | — | SEC |
| 6 de Junho de 2005 | — | Declaração inicial | Campanha no conselho | SEC | |
| OrbiMed Advisors LLC, OrbiMed Capital LLC, Samuel D. Isaly, Richard B. Brewer, Joseph Klein, III ×2 declarações | 6 de Maio de 2005 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 110 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| GNOM · Global X Funds | 4,09% | 39.792 NS | 31 de Maio de 2026 | N-PORT |
| PBE · Invesco Exchange-Traded Fund Trust | 2,89% | 164.036 SH | 8 de Agosto de 2026 | Diário |
| BBP · ETFis Series Trust I | 1,61% | 17.750 NS | 30 de Abril de 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,27% | 12.555 NS | 30 de Abril de 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,14% | 40.919 NS | 30 de Abril de 2026 | N-PORT |
| RNIN · EA Series Trust | 1,12% | 31.743 NS | 30 de Abril de 2026 | N-PORT |
| IBB · iShares Trust | 0,90% | 1.397.505 SH | 8 de Agosto de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,84% | 10.516 SH | 8 de Agosto de 2026 | Diário |
| LABU · Direxion Shares ETF Trust | 0,84% | 80.485 NS | 30 de Abril de 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,83% | 133.988 NS | 30 de Abril de 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,69% | 1.977 NS | 30 de Abril de 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 0,64% | 18.230 NS | 31 de Maio de 2026 | N-PORT |
| SMMV · iShares Trust | 0,63% | 29.931 SH | 8 de Agosto de 2026 | Diário |
| BIB · ProShares Trust | 0,55% | 7.110 NS | 31 de Maio de 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,54% | 3.021 NS | 31 de Maio de 2026 | N-PORT |
| ABCS · EA Series Trust | 0,48% | 948 NS | 29 de Maio de 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,44% | 259 NS | 29 de Maio de 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,43% | 24.857 NS | 30 de Abril de 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,38% | 26.083 SH | 8 de Agosto de 2026 | Diário |
| XJH · iShares Trust | 0,37% | 26.156 SH | 8 de Agosto de 2026 | Diário |
| IJK · iShares Trust | 0,36% | 643.881 SH | 8 de Agosto de 2026 | Diário |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 108.709 SH | 8 de Agosto de 2026 | Diário |
| IJH · iShares Trust | 0,33% | 6.668.981 SH | 8 de Agosto de 2026 | Diário |
| PTMC · Pacer Funds Trust | 0,30% | 22.042 NS | 30 de Abril de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,30% | 2.559.860 SH | 8 de Agosto de 2026 | Diário |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,30% | 312.378 SH | 8 de Agosto de 2026 | Diário |
| IJJ · iShares Trust | 0,29% | 422.817 SH | 8 de Agosto de 2026 | Diário |
| DFSV · Dimensional ETF Trust | 0,29% | 400.897 NS | 30 de Abril de 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,28% | 31.691 NS | 30 de Abril de 2026 | N-PORT |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,27% | 71.381 SH | 8 de Agosto de 2026 | Diário |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,25% | 24.275 NS | 30 de Abril de 2026 | N-PORT |
| ISCV · iShares Trust | 0,24% | 27.744 SH | 8 de Agosto de 2026 | Diário |
| MVV · ProShares Trust | 0,24% | 6.639 NS | 31 de Maio de 2026 | N-PORT |
| JIII · Janus Detroit Street Trust | 0,22% | 6.823 NS | 30 de Abril de 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,21% | 3.182 NS | 30 de Abril de 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,21% | 77.243 NS | 30 de Abril de 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,20% | 518.955 NS | 31 de Maio de 2026 | N-PORT |
| IYH · iShares Trust | 0,19% | 114.684 SH | 8 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | 0,18% | 8.611 SH | 8 de Agosto de 2026 | Diário |
| UMDD · ProShares Trust | 0,17% | 927 NS | 31 de Maio de 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,16% | 19.998 SH | 8 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,16% | 84.082 NS | 30 de Abril de 2026 | N-PORT |
| FNDA · SCHWAB STRATEGIC TRUST | 0,16% | 245.186 NS | 31 de Maio de 2026 | N-PORT |
| SMMD · iShares Trust | 0,16% | 95.606 SH | 8 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,15% | 534.462 SH | 8 de Agosto de 2026 | Diário |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,15% | 31.223 SH | 8 de Agosto de 2026 | Diário |
| VFVA · VANGUARD WELLINGTON FUND | 0,14% | 20.990 SH | 8 de Agosto de 2026 | Diário |
| DFAS · Dimensional ETF Trust | 0,14% | 361.639 NS | 30 de Abril de 2026 | N-PORT |
| ISCG · iShares Trust | 0,13% | 21.146 SH | 8 de Agosto de 2026 | Diário |
| VB · VANGUARD INDEX FUNDS | 0,13% | 4.433.137 SH | 8 de Agosto de 2026 | Diário |